PepVault
/ database / Senolytic Peptide

FOXO4-DRI

Also: FOXO4 DRI

Targeted senolytic — clears 'zombie cells' in pre-clinical models.

Evidence
anecdotal
Legal status
research only
Half-life
Unclear in humans
Routes
subq
View on Limitless LifeAdd to compare
What it is

FOXO4-DRI was developed by Peter de Keizer's lab and induces apoptosis selectively in senescent cells. In aged mice it restored fitness and fur density.

Mechanism

Disrupts FOXO4-p53 interaction in senescent cells, triggering their apoptosis.

Outcomes it's matched to
Safety

Unknown long-term human safety.

  • Pregnancy
  • Active malignancy
Legal context

Research use only. No human safety data.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault